has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug troculeucel, intended for the treatment of moderate Alzheimer's disease (AD).

Now he believes the (virtual) sky is the limit. Alzheimer’s might be linked to gum disease bacteria, scientists say Recent studies link Alzheimer's to bacteria that also cause chronic gum disease.

A new artificial intelligence model measures how fast a patient's brain is aging and could be a powerful new tool for understanding, preventing and treating cognitive decline and dementia.

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease. NKGen will benefit from increased FDA interactions, ...

has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug troculeucel, intended for the treatment of moderate Alzheimer's disease (AD).